[Skip to Content]
[Skip to Content Landing]
March 22, 1976

Improved Chemotherapy for Small-Cell Undifferentiated Lung Cancer

Author Affiliations

From the departments of hematology-oncology (Dr Einhorn) and pulmonary medicine (Drs Fee and Farber), Indiana University Medical School, Indianapolis; and the Department of Developmental Therapeutics, University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston (Drs Livingston and Gottlieb).

JAMA. 1976;235(12):1225-1229. doi:10.1001/jama.1976.03260380019019

Bleomycin sulfate, doxorubicin hydrochloride, cyclophosphamide, and vincristine sulfate combination chemotherapy was given to 29 patients with small-cell undifferentiated lung cancer. Only four of these patients had limited disease, and in these patients there was 100% complete remission; two of these four patients remain in complete remission at more than 52 and 60 weeks. Of the 25 patients with generalized disease, 18 (72%) had neoplasm regression (>50%), including two with complete remission (8%). The median duration of remission was 25 weeks. The median survival time from diagnosis was 39 weeks and that from initiation of therapy, 35 weeks. The drug regimen was well tolerated, and although substantial leukopenia was produced, there were only three patients in whom granulocytopenic infections developed. There was only one drug-related death.

(JAMA 235:1225-1229, 1976)